Literature DB >> 27474328

Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography.

Ijin Joo1,2, Jeong Min Lee1,2,3, Dong Ho Lee1,2, Su Joa Ahn1,2, Eun Sun Lee4, Joon Koo Han1,2,3.   

Abstract

PURPOSE: To investigate the Liver Imaging Reporting and Data System (LI-RADS) v2014 categorization of hepatocellular carcinomas (HCCs) on gadoxetic acid-enhanced magnetic resonance imaging (Gd-EOB-MRI) in comparison with multiphasic multidetector computed tomography (MDCT).
MATERIALS AND METHODS: Our Institutional Review Board approved this retrospective study and waived the requirement for informed consent. We included 182 high-risk patients with 216 pathologically confirmed HCCs who underwent both Gd-EOB-MRI at 1.5 or 3T and multiphasic MDCT. Two independent radiologists assessed the presence or absence of major HCC features and assigned LI-RADS categories before and after considering ancillary features on both MRI and MDCT. Finally, sensitivities of LR-5/5v and frequencies of major HCC features were compared between MRI and MDCT using the McNemar test.
RESULTS: Sensitivities of LR-5/5v were not significantly different between MRI and MDCT (63.4% [137/216] vs. 64.4% [139/216], P = 0.831; 60.6% [131/216] vs. 60.6% [131/216], P = 0.868, for reviewers 1 and 2, respectively). Among major HCC features seen on consensus review, washout and capsule appearance were less frequently observed on MRI than on MDCT (69.0% [149/216] vs. 87.0% [188/216], P < 0.001 and 17.1% [37/216] vs. 31.5% [68/216], P < 0.001), while no significant differences were found for arterial hyperenhancement (88.9% [192/216] vs. 84.7% [183/216], P = 0.081). Ancillary features led to category changes in 18.1% (39/216) of nodules on MRI (all, LR-3 to LR-4), while no changes were seen on MDCT.
CONCLUSION: Using LI-RADS, Gd-EOB-MRI showed comparable sensitivity to multiphasic MDCT for the diagnosis of HCCs, and ancillary features of MRI frequently led to the upgrade of nodules from LR-3 to LR-4. LEVEL OF EVIDENCE: 3 J. Magn. Reson. Imaging 2017;45:731-740.
© 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  gadoxetic acid-enhanced MRI; hepatocellular carcinoma; liver imaging reporting and data system (LI-RADS); multiphasic MDCT

Mesh:

Substances:

Year:  2016        PMID: 27474328     DOI: 10.1002/jmri.25406

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  19 in total

1.  Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?

Authors:  Ijin Joo; Jeong Min Lee; Dong Ho Lee; Ju Hyeon Jeon; Joon Koo Han
Journal:  Eur Radiol       Date:  2018-09-25       Impact factor: 5.315

Review 2.  Pitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS).

Authors:  Yeun-Yoon Kim; Jin-Young Choi; Claude B Sirlin; Chansik An; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2018-08-16       Impact factor: 5.315

3.  Characterization of liver nodules in patients with chronic liver disease by MRI: performance of the Liver Imaging Reporting and Data System (LI-RADS v.2018) scale and its comparison with the Likert scale.

Authors:  Andrea Esposito; Valentina Buscarino; Dario Raciti; Elena Casiraghi; Matteo Manini; Pietro Biondetti; Laura Forzenigo
Journal:  Radiol Med       Date:  2019-10-05       Impact factor: 3.469

4.  Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?

Authors:  Kyoung A Baek; Seung Soo Kim; Hyeong Cheol Shin; Jeong Ah Hwang; Seo-Youn Choi; Woong Hee Lee; Chan Ho Park; Hyoung Nam Lee; Nam Hun Heo
Journal:  Abdom Radiol (NY)       Date:  2020-09

5.  LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.

Authors:  Ji Soo Song; Eun Jung Choi; Seung Bae Hwang; Hong Pil Hwang; HyeMi Choi
Journal:  Eur Radiol       Date:  2018-06-19       Impact factor: 5.315

6.  The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies.

Authors:  Jiangfa Li; Jiming Wang; Liping Lei; Guandou Yuan; Songqing He
Journal:  Eur Radiol       Date:  2019-06-27       Impact factor: 5.315

7.  LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations?

Authors:  Roberto Cannella; Federica Vernuccio; Michela Antonucci; Domenico Salvatore Gagliano; Francesco Matteini; Massimo Midiri; Giuseppe Brancatelli
Journal:  Eur Radiol       Date:  2021-09-20       Impact factor: 7.034

8.  LI-RADS v2017 categorisation of HCC using CT: Does moderate to severe fatty liver affect accuracy?

Authors:  Seung Soo Kim; Jeong Ah Hwang; Hyeong Cheol Shin; Seo-Youn Choi; Tae Wook Kang; Sung Shick Jou; Woong Hee Lee; Suyeon Park; Nam Hun Heo
Journal:  Eur Radiol       Date:  2018-08-02       Impact factor: 5.315

Review 9.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

Review 10.  Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients.

Authors:  Victoria Chernyak; Kathryn J Fowler; Aya Kamaya; Ania Z Kielar; Khaled M Elsayes; Mustafa R Bashir; Yuko Kono; Richard K Do; Donald G Mitchell; Amit G Singal; An Tang; Claude B Sirlin
Journal:  Radiology       Date:  2018-09-25       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.